HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 22, No 02, February 2018 – Searching for the fountain of youth       » Chinese researchers cloned monkeys       » National Science and Technology Prizes       » Highlights from the State Natural Science Award       » Highlights from the State Technological Invention Award      
INSIDE INDUSTRY
DSM and Tunitas Therapeutics to develop lead allergy therapeutic

DSM Pharmaceutical Products, a custom manufacturing and technology business of Royal DSM, has entered an agreement with Tunitas Therapeutics of San Francisco, USA, an early stage drug development company dedicated to the discovery and development of a broad platform of therapeutic proteins for allergies.

The contract covers the initiation of process development activities by DSM for Tunitas' lead Fc-fusion protein for the treatment of asthma and other allergic diseases. The intended manufacturing site is DSM Biologics' Brisbane facility.

"We are delighted to be working with DSM Biologics for the production of Tunitas' first clinical candidate." said Nolan Sigal, President and CEO of Tunitas Therapeutics. "DSM has an outstanding and well-earned reputation for the production of biologics of the highest quality. Furthermore, the opening of the DSM's state-of-the-art facility in Brisbane fits nicely with our strategy to begin development activities in Australia."

Manja Bouman, President of DSM Biologics, commented "It is an honor to support the development of Tunitas' promising drug candidate from our facilities. We are impressed with the potential of this product and the health benefit to treat the millions of patients whose asthma is poorly-controlled on their current therapeutic regimens."

DSM Biologics, a business unit of DSM Pharmaceutical Products, focuses on optimizing mammalian-based biopharmaceutical manufacturing through its unique set of technologies and expertise. In addition to an R&D and manufacturing site in Groningen, The Netherlands, DSM has opened operations in Brisbane, Australia, with the support of the Governments of Queensland and the Commonwealth. The Brisbane facility is DSM's blueprint for its 'biologics plant of the future' for the production of biopharmaceuticals. DSM's proprietary technologies drive down cost, processing times and capital requirements to meet market demand for developing affordable lifesaving medications.

Source: B3C Newswire

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
news Separation of conjoined twins presents surgical and ethical challenges for MassGeneral Hospital for Children staff
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Nutrition / Women in Science
April:
Digestive health / Intellectual property
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy